How Can Specialty Pharmacies Benefit from Clinical Outcomes Data?

Newman: I think that as a specialty pharmacy industry we’ve been really dependent on metrics such as MPR (medication possession ratio) and (PDC) proportion of days covered—things that we can get from traditional specialty pharmacy claims data, dispense data.

But I think what we’re being challenged to do is really show good outcomes. What we can’t measure in claims data is outcomes, so I think that’s really going to be the next thing we need to focus on.